LBA-004Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. (24th June 2018) - Bendell, J; Ciardiello, F; Tabernero, J; Tebbutt, N; Eng, C; Di Bartolomeo, M; Falcone, A; Fakih, M; Kozloff, M; Segal, N; Sobrero, A; Shi, Y; et al.